Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS103 in photosensitive epilepsy
NCT05678881Phase 1Terminated
- Sponsor
- Receptor Life Sciences
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in photosensitive epilepsy (PSE) (3 arms), sponsored by Receptor Life Sciences. Primary endpoints: Incidence and severity of adverse events at 1 week and Change in photoparoxysmal response at 1 week. Started Apr 2022; status: terminated.
02
Drugs
cannabidiol
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT05678881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678881.